- The $1.5 billion startup Proteus Digital Health makes “smart” pills, which use sensors embedded in the medication to track when patients take them.
- The sensor technology powers the $1,650-a-month drug Abilify MyCite, which was the first digital pill approved by the FDA.
- But Proteus has also faced criticism about whether patients using the tech take their pills more consistently, as well as on ethical issues.
- During the CB Insights Future of Health conference on Wednesday, Proteus CEO Andrew Thompson rebutted many of these concerns. He pointed to a new study as evidence that the tech could help people deemed “too risky” by their health insurers for expensive hepatitis C medications.
- Click here for more BI Prime stories.
The $1.5 billion startup Proteus Digital Health makes “smart” pills that track when patients take their meds. The model is one that many are betting could be the future of medicine — but it has also been the subject of a wave of criticism.
Proteus CEO and cofounder Andrew Thompson pushed back against many of those concerns on Wednesday, saying that Proteus’ tech is directed at making prescription drugs work better for patients. He also pointed to a new study the company was releasing as evidence that the products could help those deemed “too risky” by their health insurers for expensive medications.
“Drugs don’t work if you don’t take them,” Thompson said, speaking with Business Insider senior healthcare reporter Emma Court on Wednesday at CB Insights’ Future of Health conference.
Proteus’ “smart” pills, which have sensors embedded in them, track when patients take a given drug and, with their permission, give people like doctors and caregivers access to the data. A sensor patch worn by the patient tracks that activity and records it on an app.
Proteus first debuted this model with the drug Abilify MyCite, which is intended for conditions like schizophrenia and, in 2018, was the first digital pill approved by the FDA.
In January, the company launched digital-oncology medicines, hoping to ensure that patients complete oral-chemotherapy cycles while oncologists gain new insights into their patients’ treatment progress and overall health status.
Read more:A Silicon Valley company just launched ‘smart’ cancer pills that track you with tiny sensors stamped into your medications
Skepticism as to whether the medication sensors improve patient’s taking their medication
However, research on whether these types of pills actually help patients take their medications when they should remains unclear, Business Insider previously reported.
A Proteus-sponsored study of about 100 patients with hypertension and type 2 diabetes suggested that its digital pills might be an improvement on regular pills, but the results were somewhat mixed. The researchers behind the study found Proteus’ digital pills led to slightly better measures of blood pressure. The study couldn’t conclude that the tech improved rates of medication adherence — or whether patients took their pills when they were supposed to — because it didn’t measure that for study participants who got non-digital pills.
Notably, though, an analysis in BMJ this summer said the FDA’s approval of Abilify MyCite was based on weak evidence. And Abilify MyCite’s label says that the technology hasn’t been shown to improve patient compliance with their medications. Thompson said at the conference that was more a reflection of the difficulties of conducting studies, as the control group for the studies are difficult to maintain.
Proteus presents new data to combat skeptics
As a response to the criticism, during the conference, Thompson pointed to data from a new study conducted by Proteus that would be published in November. The study will be presented at a conference that month, and an abstract is available online.
The study looked at people living with hepatitis C to see if the technology could help patients take their medications and lead to the disease being cured.
The study looked at 288 patients from 18 medical centers across the US who were considered to be at risk of not taking their medicines regularly. The results from the study showed that 99.5% of the patients in the study were cured. The study didn’t compare the Proteus pills with other hepatitis C treatments.
Thompson said the point of the study was to show that any patient, regardless of social determinants or the conditions of their environment, could be successful with drug therapy.
Focus on value-based care, not cost
Whether tech like Proteus’ also adds costs to the US healthcare system is an open question. Abilify MyCite, for instance, costs $1,650 a month, much more than the inexpensive generic, The Washington Post reported.
Thompson responded to this at the conference by saying that his company’s goal was to focus on value, through better health outcomes for patients rather than the cost of treating patients.
“If you don’t take cheaper generics, they aren’t any good,” he said.
In the hepatitis C study, Thompson outlined the potential for high costs in the healthcare system if a patient experienced liver failure as a result of not taking their medication. Similarly, with Abilify MyCite, there are potentially severe consequences of people with schizophrenia missing doses.
He said the monthly cost of Proteus’ drug technology would be less than the potentially high, long-term costs to the healthcare system if patients didn’t take their medications.
“The patient learns their habits to see how they use their medicine. So does their family, so does their healthcare team. It gives the patient comfort,” he said.
This article was initially published on October 3 and has been updated.